STEROID HORMONE WITHDRAWAL SYNDROMES: Pathophysiology and Clinical Significance
- 1 May 1997
- journal article
- Published by Elsevier in Urologic Clinics of North America
- Vol. 24 (2) , 421-431
- https://doi.org/10.1016/s0094-0143(05)70389-x
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variablesCancer, 1995
- Complete Remission of Hormone Refractory Adenocarcinoma of the Prostate in Response to Withdrawal of DiethylstilbestrolJournal of Urology, 1995
- Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancerThe American Journal of Medicine, 1995
- Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetateUrology, 1995
- Response of Carcinoma of the Prostate to Withdrawal of FlutamideBritish Journal of Urology, 1993
- Response to Flutamide Withdrawal in Advanced Prostate Cancer in Progression Under Combination TherapyJournal of Urology, 1993
- Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I TrialJNCI Journal of the National Cancer Institute, 1993
- DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reactionThe Prostate, 1993
- High-dose intravenous estrogen therapy in advanced prostatic carcinomaUrology, 1989
- Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinomaCancer, 1984